Literature DB >> 10534507

Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange.

M B Andresdottir1, N Ajubi, S Croockewit, K J Assmann, L B Hibrands, J F Wetzels.   

Abstract

BACKGROUND: Focal glomerulosclerosis (FGS) can recur after renal transplantation and prognosis is poor in untreated patients. A circulating plasma factor has been implicated in the pathogenesis of a recurrent FGS and treatment with plasma exchange has proven effective in decreasing proteinuria in some patients.
METHODS: We retrospectively studied the course of disease in patients with recurrent FGS, transplanted in our centre. Seven patients transplanted between 1991 and 1997, received treatment with plasma exchange, whereas 10 patients, transplanted between 1973 and 1991, were left untreated and served as historical controls.
RESULTS: The time of onset of proteinuria (>3.5 g/day) was comparable in the untreated and treated patients (9 and 10 days respectively), as was the average proteinuria at that time (5.5 and 5.8 g/day respectively). In the untreated patients, proteinuria persisted and eventually all grafts were lost, on average 43 months after the diagnosis of a recurrence. In five cases (50%) the recurrence was the single cause of graft loss. The clinical course was different in the seven patients who were treated with plasma exchange. In five of these patients, the recurrence occurred within 3 weeks after transplantation. Plasma exchange was started 1-14 days after onset of proteinuria in these patients. Two lost their grafts after 0.7 and 1.0 months because of untreatable rejection. In the remaining three patients the plasma exchange resulted in abrupt disappearance of the proteinuria, and the response has been lasting for 2-3.2 years. In these patients the only histological abnormality was foot effacement on electron-microscopy. In two patients the recurrence became manifest at 9 weeks and 5.8 years after transplantation respectively. These two patients relapsed after the initial course of plasma exchange, but responded to repeated session, and are currently being treated once a month. They have been followed for 1. 7 and 1.4 years after the onset of proteinuria and their urinary protein levels are 0.23 and 1.2 g/10 mmol creatinine.
CONCLUSIONS: The prognosis of untreated recurrent FGS is poor. Treatment with plasma exchange can lead to complete remission of proteinuria and relapsing patients may respond to repeated sessions. Best results are obtained when plasma exchange is started early, when there are no visible lesions on light-microscopy.

Entities:  

Mesh:

Year:  1999        PMID: 10534507     DOI: 10.1093/ndt/14.11.2650

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

Review 2.  Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.

Authors:  Mirco Belingheri; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-03       Impact factor: 3.902

3.  Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children.

Authors:  A D Schachter; W E Harmon
Journal:  Pediatr Transplant       Date:  2001-12

4.  Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.

Authors:  Margret E Bock; Heather E Price; Lorenzo Gallon; Craig B Langman
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 8.237

5.  Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation.

Authors:  Gabriel M Cara Fuentes; Carmen Garcia Meseguer; Antonia Peña Carrion; Marta Melgosa Hijosa; Araceli Garcia-Pose; Angel Alonso Melgar; Mercedes Navarro Torres
Journal:  Pediatr Nephrol       Date:  2009-12-03       Impact factor: 3.714

6.  Probability, predictors, and prognosis of posttransplantation glomerulonephritis.

Authors:  Worawon Chailimpamontree; Svetlana Dmitrienko; Guiyun Li; Robert Balshaw; Alexander Magil; R Jean Shapiro; David Landsberg; John Gill; Paul A Keown
Journal:  J Am Soc Nephrol       Date:  2009-02-04       Impact factor: 10.121

7.  Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab.

Authors:  Christine Sethna; Corinne Benchimol; Hilary Hotchkiss; Rachel Frank; Lulette Infante; Suzanne Vento; Howard Trachtman
Journal:  J Transplant       Date:  2011-04-26

8.  Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients.

Authors:  Hoon Suk Park; Yuah Hong; In O Sun; Byung Ha Chung; Hyung Wook Kim; Bum Soon Choi; Cheol Whee Park; Dong Chan Jin; Yong Soo Kim; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2014-06-27       Impact factor: 2.884

9.  Remission of post-transplant focal segmental glomerulosclerosis with angiotensin receptor blockers.

Authors:  S B Bansal; S K Sethi; P Jha; R Duggal; V Kher
Journal:  Indian J Nephrol       Date:  2017 Mar-Apr

10.  Preoperative Low-Density Lipoprotein Apheresis for Preventing Recurrence of Focal Segmental Glomerulosclerosis after Kidney Transplantation.

Authors:  Akihito Sannomiya; Toru Murakami; Ichiro Koyama; Kosaku Nitta; Ichiro Nakajima; Shohei Fuchinoue
Journal:  J Transplant       Date:  2018-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.